Browse the evidence

Methionine restriction (0.17% dietary methionine) reduces visceral fat mass and preserves insulin sensitivity in aging male rats independently of energy restriction.

This study suggests that restricting methionine intake to 0.17% of the diet can significantly reduce visceral fat and improve insulin sensitivity in aging male rats, independent of calorie intake. While this is a robust finding in rats, direct application to humans requires further research, as human metabolism and dietary requirements differ significantly from Fischer 344 rats.

In human obesity, elevated circulating leptin levels do not result in weight loss or reduced adiposity due to central leptin resistance, primarily caused by impaired transport across the blood-brain barrier and downstream signaling defects.

Having high leptin levels does not mean your body is successfully managing your weight. In obesity, the brain stops listening to leptin signals due to transport and signaling issues. This is not a permanent genetic sentence but a reversible physiological state. Weight loss can improve leptin sensitivity, breaking the cycle of resistance.

Prenatal exposure to the organochlorine pesticide DDT and its metabolite DDE increases the risk of developing metabolic syndrome (including obesity, insulin resistance, and hypertension) in offspring, primarily through epigenetic programming of energy expenditure and hypothalamic development rather than increased caloric intake.

If you have a family history of metabolic syndrome, consider that your risk may be influenced by environmental exposures your mother encountered during pregnancy, not just your current diet. While you cannot change your prenatal history, being aware of this risk factor allows for earlier screening and more aggressive management of blood pressure and glucose levels, as your body may be predisposed to store fat and resist insulin due to early-life programming.

Mitochondrial dysfunction is not sufficient to cause aging or limit lifespan in animals, as evidenced by mutants with severe defects living normal or extended lives.

Focus on overall metabolic health rather than trying to eliminate all mitochondrial stress. Some level of mitochondrial stress (e.g., from exercise) may trigger protective mechanisms that support longevity, whereas severe dysfunction without adaptive responses is harmful.

Loss of the mitochondrial protein BNip3 in the liver causes hepatic steatosis and steatohepatitis by increasing lipid synthesis, reducing fatty acid oxidation, and impairing mitochondrial integrity.

Maintaining healthy mitochondrial turnover (mitophagy) is crucial for liver health. While increasing mitochondrial biogenesis (e.g., through exercise) is generally beneficial, it must be balanced with the clearance of damaged mitochondria. Disruption in this balance can lead to fatty liver disease, even if total mitochondrial numbers appear high.

BNip3 is required for proper hepatic glucose output during fasting; its absence impairs gluconeogenesis and glycogenolysis, leading to hypoglycemia.

Fasting requires a functional liver to maintain blood sugar. If your liver's ability to clear damaged mitochondria (via BNip3) is compromised, you may experience hypoglycemia or difficulty maintaining energy levels during fasting periods.

Genetic deficiency of the enzyme CD38 protects against high-fat diet-induced obesity by enhancing energy expenditure and preventing glucose intolerance.

This research suggests that the enzyme CD38 plays a critical role in how our bodies store fat when eating a high-fat diet. By depleting NAD, CD38 inhibits the SIRT1-PGC1alpha pathway, which is responsible for burning energy and creating mitochondria. Inhibiting CD38 (as seen in knockout mice) prevents obesity even on a high-fat diet. For humans, this highlights the importance of NAD levels and SIRT1 activity (potentially influenced by exercise or compounds like resveratrol) in managing weight, rather than just caloric intake alone.

The protective effect of CD38 deficiency against obesity requires intact SIRT1 activity, mediated by increased NAD levels.

NAD levels are crucial for activating SIRT1, which in turn activates PGC1alpha to burn fat. CD38 breaks down NAD, so high CD38 activity might hinder weight loss. Maintaining NAD levels (through exercise or potentially supplements) may support this pathway.

Genetically predicted leisure television watching causally increases the risk of COVID-19 hospitalization and disease severity.

Reduce time spent watching television, as it is causally linked to higher risks of COVID-19 hospitalization and severity. This risk is mediated by metabolic factors like obesity and smoking, so replacing TV time with physical activity may mitigate these risks.

Exposure to an unfavorable intrauterine or early postnatal environment (such as maternal obesity, diabetes, or undernutrition) programs permanent physiological changes in the offspring, significantly increasing the risk of developing obesity, insulin resistance, and metabolic syndrome in adulthood.

If your mother had obesity or diabetes during pregnancy, your body may be biologically predisposed to store fat and resist insulin. This is not your fault, but it is your responsibility to manage. Prioritize a healthy diet and regular physical activity from childhood to counteract this early-life programming, as your body may be more sensitive to high-calorie environments than others.

Conventional wastewater treatment plants are ineffective at removing many endocrine-disrupting compounds, leading to their presence in surface water and drinking water supplies.

If concerned about EDCs, consider using water filters certified to remove specific contaminants like BPA or pesticides, as standard municipal treatment may not remove them. Check local water quality reports for emerging contaminants.

Increased mitochondrial respiration and biogenesis are prerequisites for the adipogenic differentiation of human mesenchymal stem cells (hMSCs); inhibiting mitochondrial function via hypoxia, rotenone, or TFAM knockdown suppresses this differentiation.

This research highlights that cellular energy metabolism is not just a byproduct but a driver of cell identity. For therapeutic applications involving stem cells (like treating obesity or heart disease), ensuring mitochondrial health and function may be as important as the signaling molecules used to direct cell growth. It suggests that metabolic interventions could potentially influence fat cell formation by targeting mitochondrial efficiency.

Accumulation of succinate and itaconate in classically activated macrophages stabilizes HIF-1alpha, which promotes further glycolysis and inflammation, creating a feedback loop.

Specific metabolites (succinate) can act as signaling molecules to lock immune cells into an inflammatory state by stabilizing key transcription factors.

High preoperative intramuscular adipose tissue content (IMAC) and low psoas muscle mass index (PMI) are independent risk factors for increased mortality after living donor liver transplantation.

For patients with liver disease or undergoing major surgery, muscle quality matters as much as muscle size. Intramuscular fat (steatosis) is a hidden risk factor that increases mortality. While you cannot easily change muscle quality at home, understanding that 'empty' muscle (low quality) is dangerous highlights the importance of comprehensive nutritional therapy and rehabilitation before surgery, not just weight loss or strength training.

Vagal afferent signaling regarding food intake is primarily driven by mechanoreceptors (IGLEs) sensing intestinal stretch, rather than chemoreceptors sensing gut peptides like GLP-1.

When taking GLP-1 medications, part of the weight loss comes from the physical feeling of fullness (stretch) in your stomach and intestines, not just a chemical signal. This is why you feel full faster and stay full longer. The drug enhances these mechanical signals to your brain.

Higher body mass index (BMI) is associated with improved overall and disease-specific survival in patients with HNSCC, with obese and overweight patients showing significantly better outcomes than normal-weight patients.

For HNSCC patients, maintaining a higher BMI (overweight or obese range) may be protective against mortality during radiotherapy. This suggests that aggressive nutritional support to prevent weight loss and preserve fat and muscle mass is crucial, as these reserves provide metabolic protection.

Conjugated equine estrogens (CEE) are less effective than endogenous estradiol at inhibiting smooth muscle cell growth and preventing neointima formation due to lower binding affinity and potency at estrogen receptors.

Not all estrogens are equal. CEE, commonly used in HRT, contains weaker estrogens (estrone, estriol) that are less potent at blocking vascular remodeling than pure estradiol. This pharmacological difference may explain why CEE trials failed to show heart benefits while estradiol trials showed some vascular improvement.

In obese insulin-resistant individuals, elevated membrane-associated Protein Kinase C (PKC) isoforms (specifically PKC-epsilon and PKC-theta) phosphorylate the insulin receptor on serine/threonine residues, thereby reducing its tyrosine kinase activity and causing insulin resistance.

This research explains why obesity often leads to insulin resistance: excess fat leads to higher Free Fatty Acids, which activate PKC enzymes in muscle. These enzymes 'clog' the insulin receptor by adding phosphate groups to the wrong spots (serine/threonine), preventing it from working efficiently. While you cannot directly control PKC levels, reducing body fat and Free Fatty Acids through diet and exercise is the primary way to reduce this specific molecular blockage.

Existing anti-diabetic medications, including Metformin, GLP-1 agonists, and Verapamil, exert part of their therapeutic effect by downregulating TXNIP expression.

If you are taking Metformin or GLP-1 agonists (like Ozempic or Trulicity), one of the reasons they work is that they lower TXNIP levels in your body. This helps your cells use insulin better and protects your pancreas. This is a known mechanism, not a side effect.

Financial conflicts of interest are prevalent among members of clinical practice guideline panels, with a significantly higher prevalence in non-government sponsored guidelines compared to government sponsored ones.

When evaluating clinical guidelines, check the funding source and panel disclosures. Non-government sponsored guidelines have a 69% rate of financial conflicts of interest, compared to 16% for government-sponsored ones. Prioritize guidelines with transparent, government or non-profit backing to minimize bias.

Depletion of Kupffer cells (liver macrophages) improves insulin signaling and hepatic insulin sensitivity in obese mice.

Targeting liver inflammation may be a viable strategy for improving insulin sensitivity, though current clinical applications of macrophage depletion are limited.

Inhibition of the Insulin/IGF-1 signaling (IIS) pathway extends lifespan by promoting the nuclear translocation of the DAF-16/FOXO transcription factor, which then activates downstream genes for stress resistance and longevity.

This research highlights that the body's insulin signaling system acts as a master switch for longevity. In model organisms, reducing the activity of this pathway (mimicking dietary restriction or stress) activates a specific transcription factor (FOXO/DAF-16) that moves to the cell nucleus to turn on protective genes. While this is a mechanistic finding in worms and mice, it suggests that metabolic health and insulin sensitivity are biologically linked to the aging process.

Intermittent administration of rapamycin (e.g., 2 mg/kg every 5 days) extends lifespan in mice while minimizing metabolic and immunological side effects associated with chronic dosing.

For healthy adults seeking longevity interventions, intermittent dosing of rapamycin (specifically 2mg/kg every 5 days) appears to offer a superior risk-benefit profile compared to daily dosing. This schedule extends lifespan in mice and avoids the metabolic and immune suppression seen with chronic use. While human trials are ongoing, this protocol represents the current best evidence for mitigating rapamycin's known side effects while preserving its anti-aging benefits.

Rapamycin exhibits sexual dimorphism in efficacy, extending lifespan significantly more in female mice than in male mice.

If rapamycin is used for longevity, women may derive greater lifespan benefits than men, potentially due to differences in drug metabolism or baseline mTOR signaling. Men may require careful monitoring for side effects like insulin resistance.